Cite
HARVARD Citation
Palandri, F. et al. (2020). Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real‐world data. Hematological oncology. 38 (3), pp. 372-380. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Palandri, F. et al. (2020). Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real‐world data. Hematological oncology. 38 (3), pp. 372-380. [Online].